{"id":821044,"date":"2025-03-04T05:51:35","date_gmt":"2025-03-04T10:51:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\/"},"modified":"2025-03-04T05:51:35","modified_gmt":"2025-03-04T10:51:35","slug":"class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\/","title":{"rendered":"Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) Seeking Recovery for Investors &#8211; Contact Levi &amp; Korsinsky"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">NEW YORK<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">March 4, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Levi &amp;\u00a0Korsinsky, LLP notifies investors in <b>Neumora Therapeutics, Inc.<\/b> (&#8220;Neumora Therapeutics, Inc.&#8221; or the &#8220;Company&#8221;) (NASDAQ: NMRA) of a class action securities lawsuit.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg\" title=\"Levi &amp; Korsinsky, LLP (PRNewsfoto\/Levi &amp; Korsinsky, LLP)\" alt=\"Levi &amp; Korsinsky, LLP (PRNewsfoto\/Levi &amp; Korsinsky, LLP)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\n        <b>CLASS DEFINITION: <\/b>The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by <span>alleged<\/span> securities <span>fraud<\/span>. This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and\/or traceable to the Offering Documents, commenced on or about <span class=\"xn-chron\">September 15, 2023<\/span>. Follow the link below to get more information and be contacted by a member of our team:<\/p>\n<p>\n        <a href=\"https:\/\/zlk.com\/pslra-1\/neumora-therapeutics-inc-lawsuit-submission-form?prid=133513&amp;wire=4\" rel=\"nofollow\">https:\/\/zlk.com\/pslra-1\/neumora-therapeutics-inc-lawsuit-submission-form?prid=133513&amp;wire=4<\/a>\n      <\/p>\n<p>\n        <b>NMRA<\/b>\u00a0investors may also contact <span class=\"xn-person\">Joseph E. Levi, Esq.<\/span> via email <a href=\"mailto:at\u00a0jlevi@levikorsinsky.com\u00a0or\" rel=\"nofollow\">at\u00a0jlevi@levikorsinsky.com\u00a0or<\/a> by telephone at (212) 363-7500.<\/p>\n<p>\n        <b>CASE DETAILS: <\/b>The filed complaint <span>alleges<\/span> that defendants made false statements and\/or concealed that: (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn&#8217;s original Phase Two trial inclusion criteria to include a patient population with moderate to severe Major Depressive Disorder, MDD, to show that Navacaprant, Neumora&#8217;s flagship therapeutic candidate, offered a statistically significant improvement in treating MDD; (2) and to that same end, the Company also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (3) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study.<\/p>\n<p>\n        <b>WHAT&#8217;S NEXT? <\/b>If you suffered a loss in Neumora Therapeutics, Inc. during the relevant time frame, you have until <b><span class=\"xn-chron\">April 7, 2025<\/span><\/b>\u00a0to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn&#8217;t require that you serve as a lead plaintiff.<\/p>\n<p>\n        <b>NO COST TO YOU: <\/b>If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. <b>There is no cost or obligation to participate.<\/b><\/p>\n<p>\n        <b>WHY LEVI &amp; KORSINSKY: <\/b>Over the past 20 years, the team at Levi &amp; Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi &amp; Korsinsky has ranked in ISS Securities Class Action Services&#8217; Top 50 Report as one of the top securities litigation firms in <span class=\"xn-location\">the United States<\/span>.<\/p>\n<p>\n        <b>CONTACT:<\/b><br \/>\n        <br \/>Levi &amp; Korsinsky, LLP <br \/><span class=\"xn-person\">Joseph E. Levi, Esq.<\/span><br \/><span class=\"xn-person\">Ed Korsinsky, Esq.<\/span><br \/>33 Whitehall Street, 17th Floor<br \/><span class=\"xn-location\">New York, NY<\/span> 10004<br \/><a href=\"mailto:jlevi@levikorsinsky.com\" rel=\"nofollow\">jlevi@levikorsinsky.com<\/a><br \/>Tel: (212) 363-7500<br \/>Fax: (212) 363-7171<br \/><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4374841-2&amp;h=558112425&amp;u=https%3A%2F%2Fwww.zlk.com%2F&amp;a=www.zlk.com\" target=\"_blank\" rel=\"nofollow\">www.zlk.com<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY32420&amp;sd=2025-03-04\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors--contact-levi--korsinsky-302390901.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors&#8211;contact-levi&#8211;korsinsky-302390901.html<\/a><\/p>\n<p>SOURCE  Levi &amp; Korsinsky, LLP<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY32420&amp;Transmission_Id=202503040545PR_NEWS_USPR_____NY32420&amp;DateId=20250304\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEW YORK , March 4, 2025 \/PRNewswire\/ &#8212; Levi &amp;\u00a0Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. (&#8220;Neumora Therapeutics, Inc.&#8221; or the &#8220;Company&#8221;) (NASDAQ: NMRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and\/or traceable to the Offering Documents, commenced on or about September 15, 2023. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/neumora-therapeutics-inc-lawsuit-submission-form?prid=133513&amp;wire=4 NMRA\u00a0investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) Seeking Recovery for Investors &#8211; Contact Levi &amp; Korsinsky&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-821044","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) Seeking Recovery for Investors - Contact Levi &amp; Korsinsky - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) Seeking Recovery for Investors - Contact Levi &amp; Korsinsky - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK , March 4, 2025 \/PRNewswire\/ &#8212; Levi &amp;\u00a0Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. (&#8220;Neumora Therapeutics, Inc.&#8221; or the &#8220;Company&#8221;) (NASDAQ: NMRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and\/or traceable to the Offering Documents, commenced on or about September 15, 2023. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/neumora-therapeutics-inc-lawsuit-submission-form?prid=133513&amp;wire=4 NMRA\u00a0investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or &hellip; Continue reading &quot;Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) Seeking Recovery for Investors &#8211; Contact Levi &amp; Korsinsky&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-04T10:51:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) Seeking Recovery for Investors &#8211; Contact Levi &amp; Korsinsky\",\"datePublished\":\"2025-03-04T10:51:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\\\/\"},\"wordCount\":495,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\\\/\",\"name\":\"Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) Seeking Recovery for Investors - Contact Levi &amp; Korsinsky - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\",\"datePublished\":\"2025-03-04T10:51:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) Seeking Recovery for Investors &#8211; Contact Levi &amp; Korsinsky\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) Seeking Recovery for Investors - Contact Levi &amp; Korsinsky - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\/","og_locale":"en_US","og_type":"article","og_title":"Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) Seeking Recovery for Investors - Contact Levi &amp; Korsinsky - Market Newsdesk","og_description":"PR Newswire NEW YORK , March 4, 2025 \/PRNewswire\/ &#8212; Levi &amp;\u00a0Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. (&#8220;Neumora Therapeutics, Inc.&#8221; or the &#8220;Company&#8221;) (NASDAQ: NMRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and\/or traceable to the Offering Documents, commenced on or about September 15, 2023. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/neumora-therapeutics-inc-lawsuit-submission-form?prid=133513&amp;wire=4 NMRA\u00a0investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or &hellip; Continue reading \"Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) Seeking Recovery for Investors &#8211; Contact Levi &amp; Korsinsky\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-04T10:51:35+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) Seeking Recovery for Investors &#8211; Contact Levi &amp; Korsinsky","datePublished":"2025-03-04T10:51:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\/"},"wordCount":495,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\/","name":"Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) Seeking Recovery for Investors - Contact Levi &amp; Korsinsky - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","datePublished":"2025-03-04T10:51:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors-contact-levi-korsinsky\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) Seeking Recovery for Investors &#8211; Contact Levi &amp; Korsinsky"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/821044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=821044"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/821044\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=821044"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=821044"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=821044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}